How many insider trades does FilingIQ track for GTHP?

FilingIQ tracks 133 Form 4 insider transactions for GTHP (GUIDED THERAPEUTICS INC), covering filings from Jan 16, 2015 onwards. 38 of those were filed in the last 90 days.

Are GTHP insiders net buyers or net sellers?

Across the full Form 4 history for GTHP, 29 transactions (22%) were open-market purchases and 7 (5%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does GTHP insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is GTHP in?

GUIDED THERAPEUTICS INC (GTHP) is classified in the Healthcare sector, specifically Medical Devices, with a current market capitalisation of $32.60M.

GTHP insider trading

OTC Markets OTCQB Healthcare

GUIDED THERAPEUTICS INC — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

133

Last 90 days

Buys / sells

22% / 5%

Market cap

$32.60M

About GUIDED THERAPEUTICS INC

Guided Therapeutics, Inc., a medical technology company, develops medical devices. It focuses on the marketing and sale of LuViva, an advanced cervical scan non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is headquartered in Peachtree Corners, Georgia.

Company website: www.guidedinc.com

GTHP insider activity at a glance

FilingIQ has scored 133 insider transactions for GTHP since Jan 16, 2015. The most recent filing in our index is dated Mar 31, 2026.

Across the full history, 29 open-market purchases and 7 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on GTHP insider trades is 59.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live GTHP trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for GTHP?: FilingIQ tracks 133 Form 4 insider transactions for GTHP (GUIDED THERAPEUTICS INC), covering filings from Jan 16, 2015 onwards. 38 of those were filed in the last 90 days.
Are GTHP insiders net buyers or net sellers?: Across the full Form 4 history for GTHP, 29 transactions (22%) were open-market purchases and 7 (5%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does GTHP insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is GTHP in?: GUIDED THERAPEUTICS INC (GTHP) is classified in the Healthcare sector, specifically Medical Devices, with a current market capitalisation of $32.60M.

Methodology & sources

Every GTHP insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.